mj@jaramillodesign.com

Flamingo Therapeutics (“Flamingo”) today announced the appointment of Ezra Cohen, MD to its Board of Directors. Dr. Cohen is a leading medical oncologist and cancer researcher who brings unique and relevant expertise in the development of drugs, especially head and neck cancer, to the Flamingo board.

Flamingo Therapeutics (“Flamingo”) today announced that the first patient has been dosed in its PEMDA-HN trial evaluating danvatirsen in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with recurrent/metastatic head and neck squamous cell

Flamingo Therapeutics (“Flamingo”) today announced the presentation of a “Trials-in-Progress”, or TiP, poster at the ESMO Congress 2023, taking place October 20-24, 2023, in Madrid, Spain.

Flamingo Therapeutics (“Flamingo”) today announced that company management will participate at several upcoming investor and industry conferences in October 2023:

Flamingo Therapeutics (“Flamingo”) today announced that it has been awarded a research grant of €1.7 million by Flanders Innovation & Entrepreneurship (VLAIO). The award represents the funding at 60% of a €2.9 million project.

Flamingo Therapeutics (“Flamingo”) today announced a presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.

Dr. Denker is a physician-scientist with over two decades of biotech and pharmaceutical industry experience in clinical development across multiple modalities and therapeutic areas, including oncology and rare disease.

Flamingo Therapeutics (“Flamingo”) and Dynacure, announced today that the companies have signed a definitive merger agreement to combine their pipelines and expertise to create a leading oncology company. 

Flamingo Therapeutics, a biotechnology company pioneering RNA-targeting therapies in oncology, today announced that Mike Garrett, Chief Executive Officer, will present a company ...